Abstract
Recent cardiovascular safety trials on sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated the significant cardiovascular and renal benefits of these medications. Diabetes organisations have revised their medication guidelines to include a focus on disease outcomes for cardiovascular disease, heart failure and renal disease. This article summarises latest evidence, guideline recommendations and current Australian Pharmaceutical Benefits Scheme requirements.
Original language | English |
---|---|
Pages (from-to) | 1423-1429 |
Number of pages | 7 |
Journal | Internal Medicine Journal |
Volume | 50 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov 2020 |